Angelo Casa

Post-colectomy enteritis with ulcerative colitis: a rare but severe inflammatory condition.

Journal: Scandinavian journal of gastroenterology

Published: December 04, 2025

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Journal: Journal of Crohn's & colitis

Published: October 13, 2025

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: June 12, 2025

Role of ustekinumab in treatment of ulcerative colitis: a narrative review.

Journal: Immunotherapy

Published: November 29, 2023

Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: March 24, 2023

Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.

Journal: Inflammatory bowel diseases

Published: January 22, 2023

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.

Journal: Journal of gastroenterology and hepatology

Published: January 16, 2023

Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease: "The Superswitchers".

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: November 24, 2022

Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: August 12, 2022

Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.

Journal: European journal of gastroenterology & hepatology

Published: February 01, 2022

Post-colectomy enteritis with ulcerative colitis: a rare but severe inflammatory condition.

Post-colectomy enteritis with ulcerative colitis: a rare but severe inflammatory condition.

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.

Role of ustekinumab in treatment of ulcerative colitis: a narrative review.

Role of ustekinumab in treatment of ulcerative colitis: a narrative review.

Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.

Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.

Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.

Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.

Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease: "The Superswitchers".

Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease: "The Superswitchers".

Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics.

Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics.

Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.

Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.

The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.

The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.

Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.

Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.